← Back to Clinical Trials
Recruiting NCT04330456

NCT04330456 Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04330456
Status Recruiting
Phase
Sponsor N.N. Petrov National Medical Research Center of Oncology
Condition Soft Tissue Sarcoma Adult
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2020-02-01
Primary Completion 2022-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Preoperative stereotactic radiation therapy in hypofractionation modeSurgeryPostoperative conformal radiation therapy in normofractionation mode

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2020-02-01 with a primary completion date of 2022-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Combined treatment of soft tissue sarcoma includes 3 steps: 1. step - preoperative stereotactic radiation therapy in hypofractionation mode 2. step - operation 3. step - postoperative conformal radiation therapy in normofractionation mode

Eligibility Criteria

Inclusion Criteria: * morphologically verified diagnosis of soft tissue sarcoma * first diagnosed tumor process * ability to perform radical surgery * signed informed consent * indications for stereotactic and conformal radiation therapy * no contraindications for radiation and surgical treatment Exclusion Criteria: * previous radiation treatment * acute infection * pregnancy, lactation * recurrent tumor * refuse to sign informed consent * conditions that can affect the outcome of treatment (immunodeficiency, tuberculosis, etc.) * tumor topography and volume that don't allow to perform stereotactic and conformal radiation therapy.

Contact & Investigator

Central Contact

Grigory Zinovev, PhD

✉ zinovevgrigory@gmail.com

📞 +79213405814

Frequently Asked Questions

Who can join the NCT04330456 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Soft Tissue Sarcoma Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04330456 currently recruiting?

Yes, NCT04330456 is actively recruiting participants. Contact the research team at zinovevgrigory@gmail.com for enrollment information.

Where is the NCT04330456 trial being conducted?

This trial is being conducted at Saint Petersburg, Russia.

Who is sponsoring the NCT04330456 clinical trial?

NCT04330456 is sponsored by N.N. Petrov National Medical Research Center of Oncology. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology